LAUSR

© 2020 International Journal of Critical Illness and Injury Science | Published by Wolters Kluwer Medknow Since emerging in December 2019, the coronavirus disease 2019 (COVID‐19) pandemic caused by the beta‐coronavirus severe acute respiratory syndrome‐related coronavirus 2 (SARS‐CoV‐2) virus has resulted in over 66.5 million cases worldwide and over 1.53 million deaths (as of December 6, 2020). Roughly 20% of patients require hospitalization, with one‐quarter of those necessitating intensive care unit (ICU) admission for reasons including refractory hypoxemia, shock, or multiple organ failure.[1,2] The lack of therapies with data demonstrating efficacy resulted in many turning to less substantiated treatments supported by case reports or series, small nonrandomized studies, or even intellectual intuition. These have included (in part) antiviral therapies, immunomodulators, blood products, and traditional medications. This editorial focuses on one such therapy: intravenous immunoglobulin (IVIG) to treat severe or critical illness induced by COVID‐19.